<DOC>
	<DOCNO>NCT01670162</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety intravitreal aflibercept injection population neovascular AMD patient previously treat 2.0 mg ranibizumab persistent PEDs .</brief_summary>
	<brief_title>On-label tReatment With Intravitreal Aflibercept injectiOn Patients With Persistent Pigment epitheliaL Detachments Neovascular Age Related Macular Degeneration ( AMD )</brief_title>
	<detailed_description>A Phase 4 study evaluate efficacy safety intravitreal aflibercept injection population neovascular AMD patient previously treat 2.0 mg ranibizumab persistent PEDs ( ROLL study ) .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Dissociative Disorders</mesh_term>
	<mesh_term>Retinal Detachment</mesh_term>
	<criteria>Previous enrollment study evaluate 2.0mg ranibizumab ( NCT 01189019 ) without early study discontinuation . The last treatment* study eye receive least 30 day enrollment study . **last study treatment either 1.0mg 2.0mg ranibizumab Presence persistent fibrovascular pigment epithelial detachment Willing able comply iwth clinic visit study related procedure Provide sign informed consent Prior treatment verteporfin , external beam radiation therapy , transpupillary thermotherapy study eye . Previous subfoveal focal laser photocoagulation involve foveal center study eye . History vitrectomy , submacular surgery , surgical intervention AMD study eye . Concurrent eye disease study eye could compromise visual acuity ( e.g . diabetic retinopathy , advanced glaucoma ) . Any concurrent intraocular condition study eye ( e.g . diabetic retinopathy glaucoma ) , opinion investigator , could either require medical surgical intervention 12 month study period prevent treat visual loss might result condition , allow progress untreated , could likely contribute loss least 2 Snellen equivalent line best correct visual acuity 12 month study period . Active intraocular inflammation ( grade trace ) study eye , history idiopathic autoimmune associate uveitis either eye . Current vitreous hemorrhage study eye . History rhegmatogenous retinal detachment macular hole ( stage 3 4 ) study eye . Active infectious conjunctivitis , keratitis , scleritis , endophthalmitis either eye . Aphakia , anterior chamber intraocular lens ( ACIOL ) unstable posterior chamber intraocular lens ( PCIOL ) . Uncontrolled glaucoma study eye ( defined intraocular pressure equal great 30 despite treatment antiglaucoma medication ) . Pregnant breastfeed woman . Sexually active men* woman childbearing potential** unwilling practice adequate contraception study ( adequate contraception measure include stable use oral contraceptive prescription pharmaceutical contraceptive 2 menstrual cycle prior screen ; intrauterine device ( IUD ) ; bilateral tubal ligation ; vasectomy ; condom plus contraceptive sponge , foam , jelly , diaphragm plus contraceptive sponge , foam jelly ) . Contraception require men document vasectomy . **Postmenopausal woman must amenorrheic least 12 month order consider child bear potential . Pregnancy test contraception require woman document hysterectomy tubal ligation .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Pigment Epithelium Eye</keyword>
	<keyword>Wet macular degeneration</keyword>
	<keyword>Macular degeneration</keyword>
</DOC>